O-GlcNAcase inhibitors (Johnson & Johnson/Villapharma Research/Universitat Rovira I Virgili)

N/A

Report date: 2025/01/26 16:03:02
NME

Base Information

Drug NameO-GlcNAcase inhibitors (Johnson & Johnson/Villapharma Research/Universitat Rovira I Virgili)
Drug Alias NameOGA inhibitors (Johnson & Johnson/Villapharma Research/Universitat Rovira I Virgili)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein O-GlcNAcase inhibitors
TargetsProtein O-GlcNAcase
Therapy Area/IndicationsNerve Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesVillapharma ResearchJohnson & JohnsonUniversity Rovira I Virgili
Inactive CompaniesN/A
Active IndicationsNerve Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A